Business Description
Sonnet BioTherapeutics Holdings Inc
NAICS : 541714
SIC : 8731
ISIN : US83548R3030
Share Class Description:
SONN: Ordinary SharesDescription
Sonnet BioTherapeutics Holdings Inc is a clinical-stage biotechnology company. The company has developed FHAB (Fully Human Albumin Binding) technology which is well suited for drug development across a range of human disease areas, including in oncology, autoimmune, pathogenic, inflammatory, and hematological conditions. The firm's pipeline products include SON-080 (low-dose IL-6), SON-1210 (IL15- FHAB-IL12), SON-1010 (IL12-FHAB), and others.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 16.16 | |||||
| Equity-to-Asset | 0.48 | |||||
| Debt-to-Equity | 0.07 | |||||
| Debt-to-EBITDA | -0.01 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | -36.41 | |||||
| Beneish M-Score | 2.83 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 68.2 | |||||
| 3-Year EPS without NRI Growth Rate | 78.9 | |||||
| 3-Year FCF Growth Rate | 65.4 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 71.36 | |||||
| 9-Day RSI | 58.85 | |||||
| 14-Day RSI | 54.33 | |||||
| 6-1 Month Momentum % | 51.65 | |||||
| 12-1 Month Momentum % | -64.43 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.74 | |||||
| Quick Ratio | 1.74 | |||||
| Cash Ratio | 1.14 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -232.1 | |||||
| Shareholder Yield % | -344.18 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -11208.53 | |||||
| Net Margin % | -11209.3 | |||||
| FCF Margin % | -14355.81 | |||||
| ROE % | -951.82 | |||||
| ROA % | -185.12 | |||||
| ROIC % | -653.01 | |||||
| ROC (Joel Greenblatt) % | -5877.64 | |||||
| ROCE % | -866.43 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 18.28 | |||||
| PB Ratio | 2.21 | |||||
| Price-to-Tangible-Book | 2.21 | |||||
| EV-to-EBIT | -0.21 | |||||
| EV-to-EBITDA | -0.21 | |||||
| EV-to-Revenue | 23.71 | |||||
| EV-to-FCF | -0.17 | |||||
| Price-to-Net-Current-Asset-Value | 3.05 | |||||
| Price-to-Net-Cash | 23.26 | |||||
| Earnings Yield (Greenblatt) % | -476.19 | |||||
| FCF Yield % | -324.27 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:SONN
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Sonnet BioTherapeutics Holdings Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 0.129 | ||
| EPS (TTM) ($) | -12.75 | ||
| Beta | 1.57 | ||
| Volatility % | 156.03 | ||
| 14-Day RSI | 54.33 | ||
| 14-Day ATR ($) | 0.124502 | ||
| 20-Day SMA ($) | 1.846535 | ||
| 12-1 Month Momentum % | -64.43 | ||
| 52-Week Range ($) | 1.08 - 26.399999 | ||
| Shares Outstanding (Mil) | 3.07 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Sonnet BioTherapeutics Holdings Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Sonnet BioTherapeutics Holdings Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Sonnet BioTherapeutics Holdings Inc Frequently Asked Questions
What is Sonnet BioTherapeutics Holdings Inc(SONN)'s stock price today?
The current price of SONN is $1.86. The 52 week high of SONN is $26.40 and 52 week low is $1.08.
When is next earnings date of Sonnet BioTherapeutics Holdings Inc(SONN)?
The next earnings date of Sonnet BioTherapeutics Holdings Inc(SONN) is 2024-05-10 Est..
Does Sonnet BioTherapeutics Holdings Inc(SONN) pay dividends? If so, how much?
Sonnet BioTherapeutics Holdings Inc(SONN) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers